Agency
National Institute of Health (NIH)
Institute
Division of Cancer Treatment (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CM073702-003
Application #
3614783
Study Section
Project Start
1987-06-30
Project End
1991-06-29
Budget Start
1988-07-28
Budget End
1989-06-29
Support Year
Fiscal Year
1988
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Atkins, M B; Lotze, M T; Dutcher, J P et al. (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105-16
Hawkins, M J; Atkins, M B; Dutcher, J P et al. (1994) A phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinoma. J Immunother Emphasis Tumor Immunol 15:74-8
Sparano, J A; Fisher, R I; Weiss, G R et al. (1994) Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors. J Immunother Emphasis Tumor Immunol 16:216-23
Atkins, M B; Sparano, J; Fisher, R I et al. (1993) Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol 11:661-70
Sparano, J A; Fisher, R I; Sunderland, M et al. (1993) Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 11:1969-77
Walpole, E T; Dutcher, J P; Sparano, J et al. (1993) Survival after phase II treatment of advanced renal cell carcinoma with taxol or high-dose interleukin-2. J Immunother Emphasis Tumor Immunol 13:275-81
Weiss, G R; Margolin, K A; Aronson, F R et al. (1992) A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol 10:275-81
Saxon, R R; Klein, J S; Bar, M H et al. (1991) Pathogenesis of pulmonary edema during interleukin-2 therapy: correlation of chest radiographic and clinical findings in 54 patients. AJR Am J Roentgenol 156:281-5
Dutcher, J P; Gaynor, E R; Boldt, D H et al. (1991) A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. J Clin Oncol 9:641-8
Margolin, K A; Aronson, F R; Sznol, M et al. (1991) Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma. J Immunother (1991) 10:214-20

Showing the most recent 10 out of 17 publications